

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Coalition For Affordable Drugs XI LLC,
Petitioner

v.

Insys Pharma, Inc.,
Patent Owner

U.S. Patent 8,835,459

PETITION FOR INTER PARTES REVIEW OF U.S. PATENT
NO. 8,835,459 AND
MANDATORY NOTICES UNDER 37 C.F.R. § 42.8

Mailed August 17, 2015

TABLE OF CONTENTS

NOTICE OF RELATED MATTERS.....2

NOTICE OF SERVICE INFORMATION3

GROUNDS FOR STANDING.....3

STATEMENT OF PRECISE RELIEF REQUESTED.....3

STATEMENT OF REASONS FOR RELIEF REQUESTED.....8

I. INTRODUCTION AND SUMMARY OF ARGUMENT8

II. THE CLAIMS UNDER CONSIDERATION.....10

III. THE ‘459 PATENT AND ITS PROSECUTION HISTORY.....12

IV. CLAIM CONSTRUCTION.....20

A. “MEAN T_{MAX}”20

B. “MEAN C_{MAX}”21

C. “AUC_{LAST}”22

D. “AUC_{INF}”22

E. “ABOUT”22

V. PERSON OF ORDINARY SKILL IN THE ART.....23

VI. CLAIMS 1-6 ARE OBVIOUS.....23

A. GROUND 1 -- CLAIM 1 IS UNPATENTABLE AS OBVIOUS OVER ROSS GB, IN VIEW OF ROSS US2006, AND THE ‘862 PATENT24

1. INDEPENDENT CLAIM 124

2. THE PRIOR ART AND ITS COMPARISON TO CLAIM 125

A. *SUBLINGUAL FORMULATION*.....25

B. *FROM ABOUT 0.001% TO ABOUT 15% BY WEIGHT FENTANYL, A FREE BASE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF*26

C. *THE SUBLINGUAL FORMULATION COMPRISING ... FROM ABOUT 20% TO ABOUT 60% BY WEIGHT OF ETHANOL*.....26

D. THE SUBLINGUAL FORMULATION COMPRISING ... FROM ABOUT 4% TO ABOUT 6% BY WEIGHT OF PROPYLENE GLYCOL27

E. ADMINISTERED SUBLINGUALLY TO HUMANS30

F. THE FORMULATION PROVIDING A MEAN T_{MAX} OF ABOUT 1.28+/-0.60 HOURS30

B. GROUND 2 -- CLAIMS 2 AND 3 ARE UNPATENTABLE AS OBVIOUS OVER ROSS GB, IN VIEW OF ROSS US2006, THE '862 PATENT, AND BREDENBERG 2003......34

1. INDEPENDENT CLAIM 234

2. THE PRIOR ART AND ITS COMPARISON TO CLAIM 235

A. SUBLINGUAL FORMULATION35

B. FROM ABOUT 0.001% TO ABOUT 15% BY WEIGHT FENTANYL, A FREE BASE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF35

C. THE SUBLINGUAL FORMULATION COMPRISING ... FROM ABOUT 50% TO ABOUT 60% BY WEIGHT OF ETHANOL36

D. THE SUBLINGUAL FORMULATION COMPRISING ... FROM ABOUT 4% TO ABOUT 6% BY WEIGHT PROPYLENE GLYCOL37

E. AFTER ADMINISTRATION TO HUMANS40

F. PROVIDES A PLASMA CONCENTRATION AFTER ADMINISTRATION TO HUMANS SELECTED FROM THE GROUP CONSISTING OF: ABOUT 60% OF THE MEAN C_{MAX} IN ABOUT 10 MINUTES, ABOUT 86% OF THE MEAN C_{MAX} BY ABOUT 20 MINUTES AND A COMBINATION THEREOF40

3. DEPENDENT CLAIM 344

4. THE PRIOR ART AND ITS COMPARISON TO CLAIM 345

A. WHEN ADMINISTERED TO HUMANS PROVIDES A PLASMA CONCENTRATION THAT IS GREATER THAN ABOUT 80% OF THE MEAN C_{MAX} FOR ABOUT 2 HOURS45

C. GROUND 3 -- CLAIM 4 IS UNPATENTABLE AS OBVIOUS OVER ROSS US2006 IN VIEW OF BREDENBERG 2003......46

1. INDEPENDENT CLAIM 446

2. THE PRIOR ART AND ITS COMPARISON TO CLAIM 447

A. *A SUBLINGUAL SPRAY FORMULATION*47

B. *400 MCG DOSE OF FENTANYL*48

C. *PROVIDES ONE OR MORE MEAN PHARMACOKINETIC VALUES
SELECTED FROM THE GROUP CONSISTING OF: AUC_{LAST} 4.863+/-1.70821
HR*NG/ML, AUC_{INF} 5.761+/-1.916 HR*NG/ML, AND AUC_{EXTRAP}
10.26+/-5.66%, WHEN ADMINISTERED TO HUMANS*.....48

**D. GROUND 4 -- CLAIMS 4 AND 5 ARE UNPATENTABLE AS OBVIOUS
OVER ROSS GB IN VIEW OF THE ACTIO LABEL.**49

1. **INDEPENDENT CLAIM 4**49

2. **THE PRIOR ART AND ITS COMPARISON TO CLAIM 4**50

A. *A SUBLINGUAL SPRAY FORMULATION*.....50

B. *400 MCG DOSE OF FENTANYL*50

C. *PROVIDES ONE OR MORE MEAN PHARMACOKINETIC VALUES
SELECTED FROM THE GROUP CONSISTING OF: AUC_{LAST} 4.863+/-1.70821
HR*NG/ML, AUC_{INF} 5.761+/-1.916 HR*NG/ML, AND AUC_{EXTRAP}
10.26+/-5.66%, WHEN ADMINISTERED TO HUMANS*.....51

3. **INDEPENDENT CLAIM 5**52

4. **THE PRIOR ART AND ITS COMPARISON TO CLAIM 5**53

A. *A SUBLINGUAL SPRAY FORMULATION COMPRISING A DOSE OF
FENTANYL*53

B. *PROVIDES A SUBSTANTIALLY DOSE PROPORTIONAL MEAN AUC_{LAST}
BASED ON A MEAN AUC_{LAST} OF ABOUT 4.863+/-1.70821 HR*NG/ML FOR A
400 MCG FENTANYL DOSE WHEN ADMINISTERED TO HUMANS*53

**E. GROUND 5 -- CLAIM 6 IS UNPATENTABLE AS OBVIOUS OVER ROSS GB
IN VIEW OF THE ACTIO LABEL, AND BREDEBERG 2003.**.....55

1. **INDEPENDENT CLAIM 6**55

2. **THE PRIOR ART AND ITS COMPARISON TO CLAIM 6**56

A. *A SUBLINGUAL SPRAY FORMULATION COMPRISING A 400 MCG DOSE
OF FENTANYL*.....56

B. *PROVIDES A MEAN F(AUC_{LAST}) OF ABOUT 0.721+/-0.199 NG/ML WHEN
ADMINISTERED TO HUMANS*56

...

VII. CONCLUSION.....59

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.